Rallybio to Merge with Avenzo Therapeutics, Securing New Strategic Path
RLYB has more than doubled off its 52-week low of $2.16 on light trading volume (0.1× avg).
Summary
Rallybio Corp has announced a definitive merger agreement with Avenzo Therapeutics. This significant development comes shortly after the company terminated its previous reverse merger agreement with Candid Therapeutics on May 4th, for which it received a $50 million termination fee. The new merger provides Rallybio with a fresh strategic direction and will fundamentally reshape its corporate structure and asset portfolio. This rapid pivot is a critical event for the small-cap biotech firm.
At the time of this announcement, RLYB was trading at $14.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.6M. The 52-week trading range was $2.16 to $16.00. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.